MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company and a leader in the development of ...

Gianfranco Pittari, chief medical officer for MaaT Pharma said ... The company said that GI-ORR at day 28 occurred in 41 out of 66 patients (62%) and consisted of complete response (CR ...

Kepler Capital analyst Christophe dombu maintained a Buy rating on MaaT Pharma (MAAT – Research Report) on March 27 and set a price target of ...